Nuvalent Sets Price for Public Offering of Common Stock Boosting Funds for Cancer Treatment Innovations
Nuvalent Sets Price for Public Stock Offering
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focusing on the development of precisely targeted therapies for cancer, has recently disclosed the pricing of its underwritten public offering of Class A common stock. This significant move is anticipated to enhance the company’s financial resources essential for pushing forward its cancer-treatment initiatives.
On November 18, 2025, the Massachusetts-based company revealed that it plans to sell 4,950,496 shares at a public offering price of $101.00 per share. Following the offering, Nuvalent expects to acquire approximately $500 million in gross proceeds, just before deducting any underwriting discounts, commissions, and other expenses associated with the offering. This capital influx is pivotal for Nuvalent as it aims to bolster its pipeline of innovative therapies tailored for specific kinase targets tied to various cancer types.
The anticipated closing date for this public offering is set for November 20, 2025, contingent on meeting customary closing conditions. Moreover, Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund IV, L.P., referred to collectively as the
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.